Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome

Anne J Novak, Deanna M. Grote, Mary Stenson, Steven C. Ziesmer, Thomas Elmer Witzig, Thomas Matthew Habermann, Brandon Harder, Kay M. Ristow, Richard J Bram, Diane F Jelinek, Jane A. Gross, Stephen Maxted Ansell

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.

Original languageEnglish (US)
Pages (from-to)2247-2253
Number of pages7
JournalBlood
Volume104
Issue number8
DOIs
StatePublished - Oct 15 2004

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Cells
Tumors
Transmembrane Activator and CAML Interactor Protein
B-Cell Activation Factor Receptor
B-Lymphocytes
Neoplasms
Immune System Diseases
Oxidoreductases
Milk
BLyS receptor
Phenotype
Survival
Therapeutics
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma : Correlation with disease activity and patient outcome. / Novak, Anne J; Grote, Deanna M.; Stenson, Mary; Ziesmer, Steven C.; Witzig, Thomas Elmer; Habermann, Thomas Matthew; Harder, Brandon; Ristow, Kay M.; Bram, Richard J; Jelinek, Diane F; Gross, Jane A.; Ansell, Stephen Maxted.

In: Blood, Vol. 104, No. 8, 15.10.2004, p. 2247-2253.

Research output: Contribution to journalArticle

@article{2aa70d3b74154292a1fb500e0bf088bc,
title = "Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome",
abstract = "BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.",
author = "Novak, {Anne J} and Grote, {Deanna M.} and Mary Stenson and Ziesmer, {Steven C.} and Witzig, {Thomas Elmer} and Habermann, {Thomas Matthew} and Brandon Harder and Ristow, {Kay M.} and Bram, {Richard J} and Jelinek, {Diane F} and Gross, {Jane A.} and Ansell, {Stephen Maxted}",
year = "2004",
month = "10",
day = "15",
doi = "10.1182/blood-2004-02-0762",
language = "English (US)",
volume = "104",
pages = "2247--2253",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma

T2 - Correlation with disease activity and patient outcome

AU - Novak, Anne J

AU - Grote, Deanna M.

AU - Stenson, Mary

AU - Ziesmer, Steven C.

AU - Witzig, Thomas Elmer

AU - Habermann, Thomas Matthew

AU - Harder, Brandon

AU - Ristow, Kay M.

AU - Bram, Richard J

AU - Jelinek, Diane F

AU - Gross, Jane A.

AU - Ansell, Stephen Maxted

PY - 2004/10/15

Y1 - 2004/10/15

N2 - BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.

AB - BLyS, recently shown to be critical for survival of normal B cells, has been found to be elevated in a number of immune disease models. A role for BLyS in the survival of malignant B cells has also been revealed and we therefore sought to identify a role for BLyS and its receptors in non-Hodgkin lymphoma (NHL). We found that tumor cells from all NHL histologic subtypes expressed one or more of 3 known receptors (BCMA, TACI, and BAFF-R) for BLyS; however, the pattern of expression was variable. We provide evidence that BLyS is expressed in tumors from patients with NHL and that BLyS levels increase as tumors transform to a more aggressive phenotype. Additionally, we provide evidence that serum BLyS levels are elevated in a subgroup of patients with NHL. In patients with de novo large B-cell lymphoma, a high BLyS level correlated with a poorer median overall survival, the presence of constitutional symptoms, and elevated values of lactic dehydrogenase. When BLyS levels were correlated with response to therapy in all patients, responding patients had a significantly lower BLyS level than those with progressive disease. In summary, we found that BLyS and its receptors represent a potentially important therapeutic target in B-cell lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=4944262288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4944262288&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-02-0762

DO - 10.1182/blood-2004-02-0762

M3 - Article

C2 - 15251985

AN - SCOPUS:4944262288

VL - 104

SP - 2247

EP - 2253

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -